JIC
AVIR icon

Johnson Investment Counsel’s Atea Pharmaceuticals AVIR Stock Holding History

Johnson Investment Counsel’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$119K Buy
25,590
+7,250
+40% +$36.1K ﹤0.01% 829
2026
Q1 		$98.7K Hold
18,340
– – ﹤0.01% 798
2025
Q4 		$65.5K Hold
18,340
– – ﹤0.01% 782
2025
Q3 		$53.2K Buy
18,340
+3,000
+20% +$10.2K ﹤0.01% 817
2025
Q2 		$55.2K Buy
+15,340
New +$45.7K ﹤0.01% 808

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Johnson Investment Counsel's AVIR Position: Q2 2026 in Review

Johnson Investment Counsel increased its Atea Pharmaceuticals (AVIR) stake by 40% in Q2 2026, buying an estimated $36.1K and bringing the position to 25,590 shares worth $119K. The position accounts for ﹤0.01% of the portfolio, ranked #829.

Johnson Investment Counsel first reported a position in AVIR in Q2 2025 and has held it in 5 quarters since. 124 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • Johnson Investment Counsel held 25,590 shares of Atea Pharmaceuticals worth $119K as of Q2 2026.
  • Johnson Investment Counsel bought 7,250 Atea Pharmaceuticals shares in Q2 2026, an estimated $36.1K.
  • Atea Pharmaceuticals made up ﹤0.01% of Johnson Investment Counsel's portfolio in Q2 2026, its #829 holding.
  • Johnson Investment Counsel first reported a position in Atea Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 124 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on Johnson Investment Counsel's 13F filing for Q2 2026, filed 23 Jul 2026.